Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 6/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 12/20 | 0.44 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19679293 | 0.90 | MTOR (0.42) | METTL3PRMT5MTORRAB9AWDR77 | |
| SCHEMBL19667347 | 0.90 | PRMT5 (0.54) | METTL3PRMT5ADKMTORRAB9A | |
| SCHEMBL19684878 | 0.90 | PRMT5 (0.54) | METTL3PRMT5ADKMTORRAB9A | |
| SCHEMBL19679285 | 0.89 | ADK (0.42) | METTL3PRMT5ADKMTORRAB9A | |
| SCHEMBL19667342 | 0.84 | SRC (0.40) | METTL3PRMT5 | |
| SCHEMBL30208005 | 0.84 | SRC (0.40) | METTL3PRMT5 | |
| SCHEMBL19679294 | 0.83 | PRMT5 (0.39) | METTL3PRMT5ADKMTORRAB9A | |
| SCHEMBL19684493 | 0.81 | PRMT5 (0.52) | METTL3PRMT5MTORRAB9AWDR77 | |
| SCHEMBL19679261 | 0.81 | PRMT5 (0.52) | METTL3PRMT5MTORRAB9AWDR77 | |
| SCHEMBL19679331 | 0.81 | ADK (0.41) | METTL3PRMT5ADKWDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | METTL3 918/4885PRMT5 1945/4885ADK 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.